Heptares Therapeutics

Best-in-Class Candidate With Potential in Treatment of CNS Diseases

Older News

WELWYN GARDEN CITY, England, May 9, 2011 - Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy